{
    "question": "What biomarkers in cerebrospinal fluid are most reliable for diagnosing Alzheimer's Disease?",
    "category": "Diagnosis",
    "essential_info": [
        "Low CSF A\u03b21-42 reflects amyloid plaque deposition and is a specific AD biomarker.",
        "Elevated CSF t-tau and p-tau reflect neurodegeneration and tau pathology, showing high sensitivity.",
        "The combination of low A\u03b21-42 and high t-tau/p-tau in CSF provides high diagnostic accuracy for AD."
    ],
    "responses": [
        {
            "model": "gemma2-9b-it",
            "general_llm": "Cerebrospinal fluid (CSF) biomarkers are valuable tools in the diagnosis of Alzheimer's disease, providing objective evidence for the presence of amyloid and tau proteins, key hallmarks of the disease. \n\nThe most reliable CSF biomarkers for diagnosing Alzheimer's disease are:\n\n* **Amyloid-beta (A\u03b2) 42:**  This protein is produced in the brain and its levels are reduced in the CSF of individuals with Alzheimer's.  Specifically, a significantly lower concentration of A\u03b242 compared to normal levels is strongly indicative of amyloid plaque buildup in the brain, a characteristic feature of Alzheimer's.\n\n* **Total Tau (t-tau):**  This protein is involved in stabilizing microtubules within nerve cells. In Alzheimer's, the tau protein becomes abnormally phosphorylated, leading to tangles inside the brain. Increased levels of t-tau in the CSF reflect this neuronal damage.\n\n* **Phosphorylated Tau (p-tau):** This form of tau protein is specifically associated with the formation of neurofibrillary tangles, another hallmark of Alzheimer's. Elevated levels of p-tau in the CSF provide strong evidence for the presence of these damaging tangles.\n\nIt's important to note that:\n\n* **CSF Analysis Requires Lumbar Puncture:** Obtaining CSF involves a lumbar puncture, a procedure that carries some risks. \n* **No Single Biomarker is Definitive:** A combination of these biomarkers, along with clinical evaluation and cognitive testing, is used to make a diagnosis.\n* **These biomarkers are still under development:** Research continues to refine their accuracy and sensitivity for diagnosis.\n\n\nLet me know if you have any other questions about Alzheimer's disease. \n\n",
            "perfect_rag": "The combination of CSF Abeta42, t-tau and p-tau levels is considered the most reliable for diagnosing Alzheimer's Disease.  \n",
            "rag_pipeline": "The most reliable cerebrospinal fluid biomarkers for diagnosing Alzheimer's disease are A\u03b2<sub>1-42</sub>, T-tau, and P-tau<sub>181</sub>. \n"
        },
        {
            "model": "llama-3.1-8b-instant",
            "general_llm": "Biomarkers in cerebrospinal fluid (CSF) have emerged as valuable tools in the diagnosis and research of Alzheimer's disease (AD). While a definitive diagnosis of AD still requires a comprehensive clinical evaluation, including neuroimaging and cognitive assessments, certain biomarkers in CSF have been identified as particularly reliable for supporting a diagnosis of AD.\n\nThe most reliable CSF biomarkers for diagnosing Alzheimer's disease include:\n\n1. **Amyloid beta 42 (A\u03b242)**: A\u03b242 is a peptide derived from the amyloid precursor protein (APP). In AD patients, the levels of A\u03b242 in CSF are typically reduced due to the accumulation of amyloid beta plaques in the brain. Low levels of A\u03b242 have been consistently associated with AD and may be used in combination with other biomarkers to support a diagnosis.\n2. **Total Tau (t-tau)**: Tau is a microtubule-associated protein involved in maintaining neuronal structure. In AD, tau becomes hyperphosphorylated, leading to its accumulation in neurofibrillary tangles. Elevated levels of t-tau in CSF are a sign of tau pathology, which is associated with AD.\n3. **Phosphorylated Tau (ptau)**: Ptau is a fragment of tau that has been phosphorylated. Elevated levels of ptau in CSF are a marker of tau pathology and have been linked to AD.\n4. **Amyloid beta 40 (A\u03b240)**: While not specific to AD, A\u03b240 levels in CSF can be used in conjunction with A\u03b242 to support a diagnosis of AD.\n\nThese biomarkers can be used to support a diagnosis of AD in various ways:\n\n- **Supporting a diagnosis**: Low A\u03b242 and high t-tau or ptau levels can support a diagnosis of AD in individuals with significant cognitive decline and typical AD symptoms.\n- **Ruling out other causes**: Elevated A\u03b242 levels can help distinguish AD from other dementias, such as frontotemporal dementia (FTD).\n- **Monitoring disease progression**: Changes in CSF biomarker levels over time can be used to monitor disease progression and assess the effectiveness of therapeutic interventions.\n\nThe use of CSF biomarkers should be interpreted in the context of a comprehensive clinical evaluation, including:\n\n- **Clinical assessment**: A thorough clinical evaluation, including cognitive impairment and functional decline.\n- **Imaging studies**: Structural and functional imaging studies, such as MRI and PET scans, to rule out other causes of cognitive decline.\n- **Genetic testing**: Genetic testing for APOE-e4, which is the strongest genetic risk factor for AD.\n\nWhile CSF biomarkers are valuable tools in the diagnosis and research of AD, their interpretation should be performed by a qualified healthcare professional.",
            "perfect_rag": "According to the provided context, the biomarkers listed in Table 1 are commonly associated with Alzheimer's Disease (AD) pathophysiology. The three core CSF biomarkers for AD pathophysiology with the highest diagnostic accuracy for early AD diagnosis are CSF Abeta42, t-tau, and p-tau. \n\nAmong these, CSF p-tau is considered a more reliable marker in AD early diagnosis due to its closer relationship with AD pathophysiology and neurofibrillary tangle formation. Specifically, p-tau in threonin-231 (P-tau231) is considered the most accurate marker of MCI conversion to AD with 80% specificity and 80% total diagnostic accuracy.",
            "rag_pipeline": "The A\u03b21-42, T-tau, and P-tau181 biomarkers in cerebrospinal fluid are considered reliable for diagnosing Alzheimer's Disease, as they have been validated and standardized for this purpose. These markers are most useful in the differential diagnosis of Alzheimer's Disease and related disorders, particularly when there are mixed pathologies or atypical presentations, and when the clinical diagnosis is ambiguous."
        },
        {
            "model": "llama-3.3-70b-versatile",
            "general_llm": "Cerebrospinal fluid (CSF) biomarkers have emerged as valuable tools for diagnosing Alzheimer's Disease (AD). The most reliable biomarkers in CSF for diagnosing AD are:\n\n1. **Amyloid-\u03b2 42 (A\u03b242)**: Low levels of A\u03b242 in CSF are associated with Alzheimer's Disease. A\u03b242 is a peptide that accumulates in the brains of individuals with AD, and its decreased presence in CSF is thought to reflect the deposition of amyloid plaques in the brain.\n2. **Tau protein (Total Tau)**: Elevated levels of total tau (t-tau) in CSF are a marker of neuronal damage and degeneration, which is a hallmark of AD.\n3. **Phosphorylated Tau (p-tau)**: High levels of p-tau in CSF are specific to Alzheimer's Disease and are thought to reflect the hyperphosphorylation of tau protein, which is a key feature of AD pathology.\n\nThe combination of these three biomarkers, often referred to as the \"CSF AD signature,\" provides a high degree of diagnostic accuracy for AD. A pattern of low A\u03b242, high t-tau, and high p-tau in CSF is highly suggestive of Alzheimer's Disease.\n\nThese biomarkers can be used to:\n\n* Support a diagnosis of AD in individuals with cognitive decline\n* Distinguish AD from other forms of dementia\n* Monitor disease progression and response to treatment\n* Identify individuals at risk of developing AD\n\nIt is essential to note that while these biomarkers are highly reliable, they should be interpreted in the context of clinical evaluation, medical history, and other diagnostic tests, such as imaging studies (e.g., MRI, PET) and cognitive assessments.\n\nThe use of these biomarkers has been endorsed by various organizations, including the National Institute on Aging and the Alzheimer's Association, and has been incorporated into clinical practice guidelines for the diagnosis of Alzheimer's Disease. However, it is crucial to remember that CSF biomarker analysis should only be performed in specialized laboratories with expertise in this area, and results should be interpreted by a qualified healthcare professional.",
            "perfect_rag": "The most reliable biomarkers in cerebrospinal fluid (CSF) for diagnosing Alzheimer's Disease (AD) are CSF Abeta42, t-tau, and p-tau. These biomarkers have been found to have the highest diagnostic accuracy for early AD diagnosis. CSF Abeta42 levels are significantly reduced in AD patients, while t-tau and p-tau levels are increased. The combination of these biomarkers, particularly the ratio of CSF t-tau/Abeta42, shows promising results in predicting future AD diagnosis. The combination of CSF Abeta42, t-tau, and p-tau levels has a sensitivity of 95% and a specificity of 83% in determining patients who will develop AD. Additionally, the combination of these biomarkers with other diagnostic procedures, such as medial temporal atrophy, can increase the accuracy of AD diagnosis. \n\nCSF Abeta42 is considered a reliable biomarker for AD diagnosis, as it is significantly reduced in AD patients and correlates with amyloid plaque formation. Total Tau protein (t-tau) shows the extent of neuronal damage and neurodegeneration in AD, while phosphorylated tau protein (p-tau) is more closely related to AD pathophysiology and neurofibrillary tangle formation. The combination of these biomarkers provides a more accurate diagnosis of AD than using them individually. \n\nOther biomarkers, such as apoptosis markers, soluble APP, inflammatory and oxidation markers, and secretases, are also being studied and may have increased future prospects for AD diagnosis. However, CSF Abeta42, t-tau, and p-tau remain the most reliable biomarkers for diagnosing Alzheimer's Disease.",
            "rag_pipeline": "The most reliable cerebrospinal fluid biomarkers for diagnosing Alzheimer's Disease are A\u03b2\u2081\u208b\u2084\u2082, T-tau, and P-tau\u2081\u2088\u2081. These validated biomarkers have been shown to have added value in the diagnosis of Alzheimer's Disease and related disorders, including cases with mixed pathologies, atypical presentations, and ambiguous clinical dementia diagnoses."
        },
        {
            "model": "meta-llama/llama-4-maverick-17b-128e-instruct",
            "general_llm": "Cerebrospinal fluid (CSF) biomarkers have emerged as valuable tools for diagnosing Alzheimer's disease (AD). The most reliable CSF biomarkers for AD are Amyloid-\u03b2 (A\u03b2) 42, total tau (t-tau), and phosphorylated tau (p-tau). \n\n1. **Amyloid-\u03b2 42 (A\u03b242):** Low levels of A\u03b242 in CSF are considered a reliable indicator of amyloid plaque formation in the brain, a hallmark of AD. The decrease in A\u03b242 is thought to result from its sequestration in amyloid plaques.\n\n2. **Total Tau (t-tau):** Elevated levels of t-tau in CSF reflect the intensity of neuronal damage or degeneration. High t-tau levels are associated with AD, but they are not specific to the disease as they can also be elevated in other neurodegenerative disorders, such as Creutzfeldt-Jakob disease.\n\n3. **Phosphorylated Tau (p-tau):** Increased levels of p-tau, particularly at threonine 181 (p-tau181), are indicative of tau pathology, another key feature of AD. P-tau is more specific to AD than t-tau, as it is less frequently elevated in non-AD dementias.\n\nThe combination of these biomarkers, often referred to as the \"A\u03b242/t-tau/p-tau\" or \"Alzheimer's signature,\" improves diagnostic accuracy. A low A\u03b242 level combined with high t-tau and/or p-tau levels is considered indicative of AD pathology.\n\nThe use of these CSF biomarkers is supported by various guidelines, including those from the National Institute on Aging-Alzheimer's Association (NIA-AA) and the International Working Group (IWG) for New Research Criteria for the Diagnosis of AD. \n\nIt is worth noting that while these biomarkers are valuable, their interpretation requires careful consideration of the clinical context, and they should be used in conjunction with other diagnostic tools, such as imaging studies and cognitive assessments, to support a diagnosis of AD. Additionally, standardization of CSF biomarker assays and establishment of clear cut-off values remain areas of ongoing research.",
            "perfect_rag": "The most reliable biomarkers in cerebrospinal fluid (CSF) for diagnosing Alzheimer's Disease (AD) are Abeta42, t-tau, and p-tau. The combination of these three biomarkers has been shown to have 95% sensitivity and 83% specificity in determining patients who will develop AD. Abeta42 is a key component of amyloid plaques, and its levels are significantly reduced in AD patients. T-tau reflects the extent of neuronal damage and neurodegeneration, and its levels are increased in AD patients. P-tau is closely related to AD pathophysiology and neurofibrillary tangle formation, and its levels are also increased in AD patients. The ratio of CSF t-tau/Abeta42 has also been found to be a promising predictor of future cognitive decline. Additionally, the combination of CSF biomarkers with other diagnostic procedures, such as MRI, can increase the accuracy of AD diagnosis.",
            "rag_pipeline": "The most reliable biomarkers in cerebrospinal fluid for diagnosing Alzheimer's Disease are A\u03b2<sub>1-42</sub>, T-tau, and P-tau<sub>181</sub>. These validated biomarkers have been found to have an added value in the differential diagnosis of Alzheimer's Disease and related disorders."
        },
        {
            "model": "qwen/qwen3-32b",
            "general_llm": "<think>\nOkay, the user is asking about the most reliable biomarkers in cerebrospinal fluid (CSF) for diagnosing Alzheimer's disease. I need to recall what I know about Alzheimer's biomarkers.\n\nFirst, I remember that Alzheimer's is characterized by amyloid plaques and neurofibrillary tangles. So, the CSF biomarkers related to these pathologies would be key. The main ones are amyloid-beta 1-42, total tau, and phosphorylated tau. Wait, but I need to make sure if this is the case. \n\nAmyloid-beta 42 in CSF: I think lower levels indicate more plaque buildup in the brain because when there's more plaque, less A\u03b242 is released into the CSF. Then there's total tau (t-tau), which might be elevated due to neuronal damage. Phosphorylated tau (p-tau), especially at certain sites like Thr181, is more specific to neurofibrillary tangles. \n\nI should mention that the combination of A\u03b242, t-tau, and p-tau is more reliable than any single marker. Studies like the ones from the Alzheimer's Disease Neuroimaging Initiative (ADNI) have shown that these biomarkers are effective in distinguishing Alzheimer's from other dementias. \n\nAlso, the ratio of A\u03b242 to A\u03b240 might be relevant, but I'm not sure if that's part of the standard panel. The user asked for the \"most reliable,\" so focusing on the established trio would be better. \n\nAre there any other biomarkers? Maybe others like neurofilament light chain (NfL) for neurodegeneration, but they're not as specific for Alzheimer's. The user is asking specifically about CSF, so peripheral biomarkers like blood tests are not relevant here. \n\nI need to clarify that while these CSF biomarkers are reliable, they are part of a diagnostic workup that includes clinical evaluation and neuroimaging. Also, lumbar puncture can be uncomfortable, so blood-based biomarkers are being developed, but the question is about CSF. \n\nCheck if there's any recent advancements. The 2018 NIA-AA criteria mentioned these CSF biomarkers. There's also the A/T/N framework, which classifies Alzheimer's pathology using amyloid (A), Tau (T), and neurodegeneration (N). CSF p-tau181 is part of the T category, right?\n\nIn summary, the key CSF biomarkers are A\u03b242 (low), t-tau (elevated), and p-tau (elevated), with p-tau181 being a specific form. The combination of these gives higher diagnostic accuracy. Also, mention that they help in distinguishing Alzheimer's from other dementias like vascular or Lewy body. \n\nWait, is the exact cutoff for A\u03b242 important? Like levels below a certain ng/mL. But maybe that's more for a technical audience. The user is asking about reliability, so explaining the direction (lower A\u03b242, higher tau) is sufficient. Also, mention that CSF biomarkers have high sensitivity and specificity for preclinical and prodromal stages. \n\nMake sure to note that while they are reliable, they aren't perfect. False positives/negatives can occur, especially in atypical cases or with genetic mutations. Also, some other conditions can affect these markers, so they need to be interpreted in context with clinical findings.\n</think>\n\nThe most reliable cerebrospinal fluid (CSF) biomarkers for diagnosing Alzheimer's disease (AD) are:\n\n### 1. **Amyloid-\u03b2 1-42 (A\u03b242)**  \n   - **Role**: Reflects the accumulation of \u03b2-amyloid plaques in the brain (a hallmark of AD pathology).  \n   - **Pattern in AD**: Levels are **reduced** in AD compared to healthy individuals. This occurs because amyloid plaques sequester A\u03b242 in the brain, decreasing its release into the CSF.  \n   - **Sensitivity/Specificity**: Strongly associated with AD but not unique to it (e.g., other neurodegenerative diseases like frontotemporal dementia may also show low A\u03b242).  \n\n### 2. **Total Tau (T-tau)**  \n   - **Role**: Indicates axonal damage and neuronal cell death from neurodegeneration.  \n   - **Pattern in AD**: Levels are **elevated** due to neuronal injury.  \n   - **Sensitivity/Specificity**: Elevated T-tau is less specific to AD than A\u03b242, as it may increase in conditions like traumatic brain injury or other dementias.  \n\n### 3. **Phosphorylated Tau (P-tau)**  \n   - **Role**: Reflects the presence of neurofibrillary tangles (another hallmark of AD).  \n   - **Pattern in AD**: Levels are **elevated** due to pathological tau aggregation.  \n   - **Specificity**: The most AD-specific of the three markers. The phosphorylation at specific sites (e.g., **Thr181**, **Thr217**, **Thr231**) further enhances its discriminative power.  \n\n---\n\n### **Why the Combination of Biomarkers is Most Reliable**  \n- **Diagnostic Panel**: The combination of **A\u03b242**, **T-tau**, and **P-tau** (particularly P-tau181) is the gold standard for CSF-based AD diagnosis.  \n- **Sensitivity/Specificity**: Studies show this triad can detect preclinical AD (even before symptoms) with **~90% accuracy** when combined with clinical and imaging data (e.g., amyloid PET scans).  \n- **Differential Diagnosis**: The pattern of these biomarkers helps distinguish AD from other dementias (e.g., low A\u03b242 with normal tau in non-AD dementias like vascular dementia).  \n\n---\n\n### **Key Clinical Contexts**  \n1. **Preclinical/Prodromal AD**: CSF biomarkers are most informative in individuals with mild cognitive impairment (MCI) to predict progression to AD.  \n2. **Amyloid-PET Correlation**: CSF A\u03b242 levels correlate with amyloid PET scan results (both assess \u03b2-amyloid pathology). However, CSF is less commonly used for amyloid detection than PET due to invasiveness.  \n3. **Limitations**:  \n   - False negatives/positives can occur in atypical AD cases (e.g., early-onset with different genetic risk factors).  \n   - CSF collection via lumbar puncture has some risk (e.g., headache), limiting its routine use.  \n\n---\n\n### **Recent Advances**  \n- **Next-Gen Tau Markers**: newer assays for **P-tau181**, **P-tau217**, or **P-tau231** show higher specificity for AD and are increasingly used in research.  \n- **Blood Biomarkers**: While CSF remains the most established, blood-based biomarkers (e.g., P-tau181) are emerging as less invasive alternatives.  \n\nIn summary, CSF A\u03b242, T-tau, and P-tau form the core biomarker panel for AD diagnosis, but their interpretation must be guided by clinical context and complementary imaging/blood tests.",
            "perfect_rag": "<think>\nOkay, so the user is asking about the most reliable cerebrospinal fluid (CSF) biomarkers for diagnosing Alzheimer's Disease (AD). Let me start by recalling what I know from the provided context. \n\nFirst, the context mentions a table that lists various biomarkers related to different aspects of AD pathophysiology. Specifically, it points out Abeta deposition, neurofibrillary tangles, neuronal degeneration, inflammation, oxidative stress, apoptosis, and neuroprotection. But the user is interested in the most reliable ones for AD diagnosis.\n\nLooking at the context, there's a detailed section on Abeta42, total tau (t-tau), and phosphorylated tau (p-tau). The text states that the core CSF biomarkers for AD are CSF Abeta42, t-tau, and p-tau. These are highlighted as having the highest diagnostic accuracy for early AD diagnosis. The passage also emphasizes that the combination of these biomarkers is even more accurate than using them individually.\n\nUnder the Abeta42 section, it's explained that reduced CSF Abeta42 levels indicate increased amyloid plaque deposition in the brain, which is a hallmark of AD. For t-tau, increased levels in CSF reflect neuronal damage and neurodegeneration. p-tau, particularly specific phosphorylated forms like P-tau231, P-tau181, are more closely tied to AD pathology due to their association with neurofibrillary tangles.\n\nThe part about combining biomarkers is crucial. The text says that when Abeta42 is low and both t-tau and p-tau are high, that profile is typical of AD. The combination of these three markers gives high sensitivity and specificity (around 95% sensitivity and 83% specificity). Additionally, ratios like t-tau/Abeta42 are more effective than individual measurements for predicting conversion from MCI to AD.\n\nI need to make sure I'm not missing any other biomarkers. The text also mentions other potential markers like APOE, inflammatory markers, etc., but they're considered novel or less established. The answer should focus on the established ones. Also, the context contrasts Abeta42 with other Abeta isoforms like 40, but the core is 42. \n\nThe user is specifically asking for the most reliable, so the answer should prioritize Abeta42, t-tau, and p-tau, highlighting their roles and the effectiveness of their combination. Also, maybe mention that ratios of these biomarkers improve diagnostic accuracy. \n\nI should verify if there's any conflicting information. For example, a study mentioned higher Abeta42 in MCI, but the consensus is that lower levels are indicative. The text addresses that most studies show lower Abeta42 in AD, so that's a detail to note but not contradict the main points.\n\nMoreover, the section on t-tau and p-tau differentiates their roles: t-tau is a marker of neuronal damage from various causes, while p-tau is more specific to AD pathology. Thus, together they enhance the diagnosis's specificity.\n\nTherefore, summarizing the key points: the three core biomarkers are Abeta42 (low), t-tau (high), and p-tau (high). Their combination and ratios provide the highest accuracy. Also, the context mentions that these biomarkers can detect preclinical AD, which is a significant advantage.\n</think>\n\nThe most reliable biomarkers in cerebrospinal fluid (CSF) for diagnosing Alzheimer's disease (AD) are **Abeta42 (A\u03b242), total tau (t-tau), and phosphorylated tau (p-tau)**. These biomarkers are integral to current diagnostic criteria and offer high accuracy in identifying AD, even in preclinical stages.  \n\n1. **Abeta42 (A\u03b242):**  \n   - **Role:** A\u03b242 is a 42-amino-acid peptide and the primary component of amyloid plaques in AD. Reduced CSF levels of A\u03b242 reflect increased amyloid plaque deposition in the brain, a hallmark of AD pathology.  \n   - **Diagnostic Utility:** CSF A\u03b242 is the most accurate individual biomarker for predicting conversion from mild cognitive impairment (MCI) to AD (79% sensitivity, 65% specificity). It is critical for detecting preclinical AD.  \n\n2. **Total Tau (t-tau):**  \n   - **Role:** Elevated t-tau levels in CSF indicate neuronal damage and neurodegeneration, as tau protein aggregates into neurofibrillary tangles (NFTs) in AD.  \n   - **Diagnostic Utility:** t-tau shows high specificity for distinguishing AD from normal aging (~86%) and depression. However, its elevation is not exclusive to AD (e.g., seen in other neurodegenerative diseases like frontotemporal dementia).  \n\n3. **Phosphorylated Tau (p-tau):**  \n   - **Role:** Abnormal phosphorylation of tau (e.g., P-tau181, P-tau231) impairs its microtubule-stabilizing function, leading to NFT formation. p-tau is more specific to AD pathophysiology than t-tau.  \n   - **Diagnostic Utility:** P-tau levels are significantly higher in AD patients and correlate strongly with MCI progression to AD (80% specificity). P-tau231 and P-tau217 are particularly effective in early diagnosis.  \n\n**Combination of Biomarkers:**  \n- The combination of **low A\u03b242** and **elevated t-tau and p-tau** provides superior diagnostic accuracy (95% sensitivity, 83% specificity) compared to individual markers.  \n- Ratios like **CSF t-tau/A\u03b242** further enhance accuracy, with 85.7% sensitivity and 84.6% specificity for AD diagnosis.  \n\n**Additional Considerations:**  \n- These biomarkers can detect preclinical AD in asymptomatic individuals.  \n- CSF A\u03b242 levels poorly correlate with blood levels, making plasma A\u03b242 less reliable as an independent marker.  \n- Combinations with other diagnostic tools (e.g., MRI, PET imaging) further improve diagnostic precision, particularly in differentiating AD from other dementias.  \n\nIn summary, the trio of CSF A\u03b242, t-tau, and p-tau forms the gold standard for AD diagnosis, providing insights into amyloid and tau pathologies critical to AD progression.",
            "rag_pipeline": "<think>\nOkay, so the user is asking about the most reliable CSF biomarkers for diagnosing Alzheimer's Disease. Let me check the context provided.\n\nThe review title mentions validating and standardizing CSF biomarkers for AD. In the section, the validated biomarkers listed are A\u03b21-42, T-tau, and P-tau181. It says they add value in differential diagnosis, especially with mixed pathologies or atypical cases. The user wants the most reliable ones, so those three must be the key. The answer should mention all three, explain their roles, and note that they're not for routine use but in specific cases. Also, it mentions they can't diagnose non-AD dementias. Need to make sure the answer is clear and based solely on the provided context without adding extra info.\n</think>\n\nThe most reliable cerebrospinal fluid (CSF) biomarkers for diagnosing Alzheimer's Disease (AD) are **A\u03b2\u2081\u208b\u2084\u2082**, **total tau (T-tau)**, and **phosphorylated tau\u2081\u2088\u2081 (P-tau\u2081\u2088\u2081)**. These biomarkers are validated for their utility in the differential diagnosis of AD, particularly in cases involving mixed pathologies, atypical clinical presentations, or ambiguous dementia diagnoses. While they enhance diagnostic accuracy in specific scenarios, they are not recommended for routine dementia diagnostic workups and cannot be used to diagnose non-AD dementias. Additionally, in cognitively healthy individuals, these biomarkers are primarily used for research purposes, such as identifying pre-clinical AD in clinical trials."
        }
    ]
}